Pravachol OTC Deal Reached Between Bayer, Bristol
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol will handle the regulatory filing of the switch NDA and advisory committee presentation for pravastatin 20 mg, while Bayer Consumer Care will handle OTC sales and marketing if FDA approves the cholesterol-lowering agent for nonprescription sale.